Neurodegenerative Diseases - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis

GervanoRA's pipeline analysis and opportunity assessment report "Neurodegenerative Diseases - Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analytics H2 2020" analyzed and assessed Neurodegenerative Diseases pipeline molecules for the opportunities in the competitive space with a major focus on the Top five indications - Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), Huntington's Disease (HD) and Multiple Sclerosis (MS).

The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Neurodegenerative diseases (NDD) industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Route of Administration, Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development.

Our comprehensive analysis on the NDD drug pipeline identified more than 600 drug candidates undergoing different stages of development- from Early R&D to Pre-registration stage for the top five indications. Among these, seven are in Pre-registration stage, 44 molecules are in the Phase 3 stage of development, 121 molecules are in Phase 2, 98 molecules are in Phase 1 and a total of 330 molecules are in non clinical stage of development.

The report has covered more than 530 companies worldwide, involved in the development of new therapeutics for the mentioned top five indications. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 15 Emerging companies in the domain and hence deriving the key leader.

GervanoRA's analytics observes more than 200 drug candidates in the Alzheimer's disease drug pipeline, 164 in Parkinson's disease drug pipeline making up the major share among the five indications. A total of 90 drug candidates for Amyotrophic Lateral Sclerosis, 88 drug candidates for Multiple Sclerosis and 59 for Huntington's disease are under development. Brief analytics have also been provided for the companies involved in the development of therapeutics for Progressive Supranuclear Palsy (PSP). More than 15 companies are focusing on the development of drug molecules for PSP.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

• ⚫ Unmet needs and Opportunities
• ⚫ Epidemiology and Epidemiology forecast till 2025 for the indications - Alzheimer's disease (AD), Parkinson's disease (PD) and Amyotrophic Lateral Sclerosis (ALS)
• ⚫ Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.) for all five indications
• ⚫ Patent Analysis of Pipeline Molecules
• ⚫ Pipeline Analysis and Estimated Pipeline Drug Approval Time lines of Key Late-Stage Drug Candidates
• ⚫ Current and Future Competitive Landscape
• ⚫ Key Established Company Profiles with SWOT Analysis
• ⚫ Emerging Company Profiles with Opportunity Assessments

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.